Global E Online Ltd vs Medtronic PLC — how do they compare? Global E Online Ltd trades at $40.82 (market cap $6.90B), while Medtronic PLC trades at $90.58 (market cap $114.45B). The key difference: Medtronic PLC is far larger — about 16.6× Global E Online Ltd's market cap, and Medtronic PLC pays a 3.22% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals.
| GLBE | MDT | |
|---|---|---|
Market Cap | $6.90B | $114.45B |
Sector | Technology | Health |
52-Week High | $42.32 | $105.35 |
52-Week Low | $27.54 | $73.75 |
Enterprise Value | $6.37B | $133.19B |
Dividend Yield | — | 3.22% |
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $42.32, up 3.17% in the past 24 hours, near its 52-week high. The stock shows bullish technical signals with strong moving average support, though RSI indicates overbought conditions. Recent earnings have been mixed, with a beat in Q4 2025 but a miss in Q1 2026. The company reported 2025 revenue of $962.20 million and net income of $68.27 million, with profitability improving into 2026. Key developments include the acquisition of Passport to enhance logistics capabilities and a $500 million share repurchase program authorized by the board.
GLBE presents a growth opportunity with robust analyst support—100% buy ratings and a consensus price target of $44.75, suggesting upside potential. However, risks include high valuation multiples like a P/E of 61.33, competitive pressures in e-commerce enablement, and insider selling by the CEO. Investors should weigh the strong growth trajectory against premium valuation and market volatility.
Medtronic (MDT) trades at $87.16, up 1.44% today, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $1.55, exceeding expectations, and maintains solid fundamentals with a 13.2% net income margin and $33.54B in revenue for 2025. Recent news highlights growth in cardiac ablation and the Hugo robotic platform, with management guiding for 11.75% organic revenue growth in Q1 2027.
The outlook is positive, supported by analyst consensus of a $98.75 price target and 60% buy ratings. Key opportunities include dividend stability and innovation in medical technology, while risks involve rising debt levels and competitive pressures. The stock's current valuation at a P/E of 23.37 offers moderate upside if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →